Immuno-Oncology Conference 2018

26 - 27 September, London, UK. Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Events Source Type: news

Related Links:

In a move that will expand research and clinical trials, Roswell Park Comprehensive Cancer Center has announced a new academic agreement with one of Europe ’s oldest educational institutions. The collaboration with the Jagiellonian University (JU) in Kraków, Poland, will include exchanges of staff, students and scientific resources to advance the development of cancer therapies for patients worldwide. Effective immediately, the deal could see excha nge of students and faculty between the two centers…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Authors: Shen T, Guo Q Abstract Proline-rich tyrosine kinase 2 (Pyk2) plays essential roles in tumorigenesis and tumor progression. Pyk2 serves as a non-receptor tyrosine kinase regulating tumor cell survival, proliferation, migration, invasion, metastasis, and chemo-resistance, and is associated with poor prognosis and shortened survival in various cancer types. Thus, Pyk2 has been traditionally regarded as an oncogene and potential therapeutic target for cancers. However, a few studies have also demonstrated that Pyk2 exerts tumor-suppressive effects in some cancers, and anti-cancer treatment of Pyk2 inhibitors m...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Conclusion: XIST exerted regulatory function in resistance of DOX possibly through miR-124/SGK1 axis, shedding new light on developing promising therapeutic strategy to overcome chemoresistance in CRC patients.Cell Physiol Biochem 2018;51:113 –128
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Authors: Anand A, Balasubramanian D, Subramanian N, Murthy S, Limbachiya S, Iyer S, Thankappan K, Sharma M Abstract Secondary head and neck lymphedema (SHNL) is a chronic condition affecting patients who have undergone treatment for head and neck cancers. It results from the disruption of normal lymphatic flow by surgery and/or radiation. The incidence of secondary head and neck lymphedema varies anywhere between 12 and 54% of all patients treated for head and neck cancer, but it is still commonly under-diagnosed in routine clinical practice. In spite of awareness of this condition, treatment has been difficult as ...
Source: Lymphology - Category: Internal Medicine Tags: Lymphology Source Type: research
Contributors : Stephen C Mack ; Michael D Taylor ; Jeremy N RichSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensGenome sequencing studies have uncovered the most frequent mutations in cancer and novel targets for therapy. While successful in many tumors, this approach has failed in others. Lethal infant ependymomas (Group A) lies at the far end of this spectrum with no recurrent focal genomic alterations, no recurrent somatic mutations, and no clear driver for targeted therapy. Despite a paucity of genetic aberrations, Group A ependymomas demonstrate widespread epigeneti...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
AbstractCurrent cancer therapy has led to tremendous improvements in outcomes. These therapies rely both on established therapies, such as anthracyclines and radiation, and molecularly-targeted therapies, such as tyrosine kinase inhibitors and immune modulators. Integrative care for patients with cancer must consider the potential effects of these therapies on a variety of organ systems, including the cardiovascular system. As a result, specialties such as cardio-oncology have developed to identify these effects, determine how to best monitor for these effects, and how to treat and ultimately prevent these effects while al...
Source: Journal of Nuclear Cardiology - Category: Nuclear Medicine Source Type: research
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy, Published online: 15 November 2018; doi:10.1038/s41416-018-0341-1High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: January 2019Source: Biomedicine &Pharmacotherapy, Volume 109Author(s): Sandeep Kumar, Navneet AgnihotriAbstractColorectal cancer (CRC) is the most common carcinoma of the digestive tract. The slow growing nature of CRC offers a great opportunity for prevention strategies. The concept of chemoprevention of colorectal cancer using plant derived natural products is gaining substantial attention because it is an inherently safe and cost-effective alternative to conventional cancer therapies. Piperlongumine (PL), a natural alkaloid present in Piper longum Linn has been reported to exhibit notable anticance...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
In conclusion, our results show that the effect of paclitaxel and oxaliplatin on the structural plasticity of DRG is retained ex vivo (for at least 30 days) and suggest the use of DRG explants derived from chemotherapy-treated mice as an efficient method to investigate the mechanisms underlying CIPN and test for possible therapeutic targets.
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
Authors: M R, S V, Ramirez JT, A V, L L Abstract Novel materials are explored very often by material scientists to design an efficient drug delivery system to target carcinoma cells. Among various nanosystem, functionalized Iron oxide Nanoparticles (IoNP) were definitely studied especially to target, endocyte and release drug moieties inside the cells. This IoNP platform is usually composed of an inorganic core and a highly biocompatible shell layer in order to perform numerous tasks at the same time, such as drug delivery, multimodal imaging, and instantaneous monitoring, along with collective therapeutic approach...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Conferences | Pharmaceuticals